The Readout Loud

378: Merck's heart disease win and the FDA's new drug regulator

This episode of The Readout Loud features a discussion on biotech news, including Pfizer's acquisition of Metsera, AbbVie ending its partnership with Calico Life Sciences, and Cochin Biosciences' drug trial results. The FDA's appointment of Richard Pazder as the head of the Center for Drug Evaluation and Research is al...

377: Melodrama at the FDA and the Pfizer-Novo bidding war

376: BridgeBio’s great week and Moderna’s unraveling

375: Startups push the FDA and biotech booms in North Carolina

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

373: Party in biotech land and AstraZeneca’s miscalculation

372: A pharma C-suite shakeup and Trump's deal with Pfizer

371: A gene therapy success in Huntington's and Trump's autism announcement

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

369: Trump, Chinese biotech, and an industry career reshaped by illness

368: New stakes in the vaccine dispute and a boost for biotech

367: The ouster of CDC's director, biotech venture firm rankings

366: Viking’s obesity flop, ‘pharma to table’ drug sales

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

363: What Vinay Prasad’s ouster means for biotech and the FDA

362: A mother’s perspective on Sarepta’s gene therapy halt

361: Inside an FDA drug rejection, and layoffs at Sarepta

360: NIH grant cuts, FDA transparency questions and biotech M&A

359: Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects